Effectiveness and safety of two diabetes medicines in older adults with type 2 diabetes: SGLT2 inhibitors versus DPP-4 inhibitors

New users of SGLT2 inhibitors had a lower risk of hospitalization for heart failure, all-cause death, and stroke compared to DPP-4 inhibitors.

• SGLT2 inhibitors are associated with a reduced risk of hospitalization for heart failure (HR 0.86).
• All-cause mortality is lower in patients using SGLT2 inhibitors compared to those on DPP-4 inhibitors (HR 0.85).
• The risk of stroke is lower for new users of SGLT2 inhibitors (HR 0.86).
• No significant difference in the risk of myocardial infarction was observed between the two groups (HR 0.95).
• Similar rates of diabetic ketoacidosis, bone fracture, and severe hypoglycaemia were found in both groups.
• Increased risks of genital infections (HR 2.44) and urinary tract infections (HR 1.05) were noted in patients using SGLT2 inhibitors.

Simplified